{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:00Z","timestamp":1786119240579,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/qai.0b013e3181b17f53","type":"journal-article","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T03:16:22Z","timestamp":1256094982000},"page":"382-386","source":"Crossref","is-referenced-by-count":42,"title":["Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection"],"prefix":"10.1097","volume":"52","author":[{"given":"Arkaitz","family":"Imaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Villar","family":"del Saz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Angels","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inma","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Ruiz","family":"de Gopegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melcior","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210131","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/135965350601100503","article-title":"Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.","volume":"11","author":"Tozzi","year":"2006","journal-title":"Antiviral Ther"},{"key":"R2-12-20210131","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1086\/425424","article-title":"Time to virologic failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.","volume":"190","author":"Mocroft","year":"2004","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"R3-12-20210131","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1086\/533418","article-title":"Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.","volume":"197","author":"Eron","year":"2008","journal-title":"J Infect Dis"},{"key":"R4-12-20210131","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R5-12-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"R6-12-20210131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"R7-12-20210131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection.","volume":"359","author":"Cooper Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"R9-12-20210131","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.qai.0000185314.56556.c3","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.","volume":"40","author":"Nelson","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-12-20210131","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","article-title":"Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"R11-12-20210131","first-page":"62","article-title":"Update of the drug resistance mutations in HIV-1: 2008.","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"R12-12-20210131","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R13-12-20210131","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/85.14.1138","article-title":"Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.","volume":"85","author":"Brundage","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R14-12-20210131","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/QAD.0b013e3282170ab1","article-title":"Pharmacokinetics and antiretroviral response to darunavir\/ritonavir and etravirine combination in patients with high-level viral resistance.","volume":"21","author":"Boffito","year":"2007","journal-title":"AIDS"},{"key":"R15-12-20210131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003495-200868010-00009","article-title":"Raltegravir.","volume":"68","author":"Croxtall","year":"2008","journal-title":"Drugs"},{"key":"R16-12-20210131","first-page":"S83","article-title":"Phenotypic and genotypic determination of resistance to TMC114: pooled analysis of POWER 1, 2, and 3 [Abstract 73].","volume":"11","author":"De Meyer","year":"2006","journal-title":"Antiviral Ther"},{"key":"R17-12-20210131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/aid.2007.0173","article-title":"Resistance profile of darunavir: combined 24-week results from the POWER trials.","volume":"24","author":"De Meyer","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R18-12-20210131","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/QAD.0b013e328307f24a","article-title":"Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.","volume":"22","author":"Delaugerre","year":"2008","journal-title":"AIDS"},{"key":"R22-12-20210131","first-page":"S34","article-title":"Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2.","volume":"12","author":"Vingerhoets","year":"2007","journal-title":"Antiviral Ther"},{"key":"R25-12-20210131","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"R26-12-20210131","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200911010-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:04:25Z","timestamp":1786039465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200911010-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181b17f53","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}